Skip to main navigation
Skip to content
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • MLE-301 Clinical Study
    • Educational Resources and Advocacy
    • Compassionate Use
  • Our Science
    • Pipeline
    • Disease Areas
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
Contact Us
Millendo
  • Our Story
  • Our Patients
    • Clinical Research Overview
    • MLE-301 Clinical Study
    • Educational Resources and Advocacy
    • Compassionate Use
  • Our Science
    • Pipeline
    • Disease Areas
    • MLE-301
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • Annual Reports & SEC Filings
    • Investor Resources
  • Join Our Team
News Releases
  • News
  • Event Calendar & Presentations

test

Tempest and Millendo have announced a merger.

 

Click here

News Releases

03/29/21
Tempest and Millendo Announce Proposed Merger Agreement
01/05/21
Millendo Therapeutics Provides Pipeline and Business Update

Shareholder Tools

Print Page Email Page RSS Feeds Email Alerts Financial Tear Sheet

US Offices

Corporate Headquarters

110 Miller Avenue, Suite 100
Ann Arbor, MI 48104
734-845-9000
millendo@millendo.com

Europe Office

 
Lyon Office

Millendo Therapeutics SAS
c/o Canopee consulting
8 rue Berjon
69009 Lyon
France
Tel +33 472 18 94 28

  • Our Story
  • Our Patients
  • Our Science
  • Investors & Media
  • Join Our Team
  • Privacy Policy
Copyright © 2021 Millendo Therapeutics, Inc. All rights reserved.
Scroll to Top